First test of new hives drug begins in humans
NCT ID NCT07181369
Summary
This is the first study in people to test the safety of a new drug called GTX-B001. It will be given as a single dose to 48 healthy volunteers and 24 people with chronic hives triggered by cold or scratching. The main goal is to see how safe the drug is and how the body processes it, while also getting an early look at whether it might help reduce hives symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité Research Organization gmbh
RECRUITINGBerlin, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fraunhofer Institute For Translational Medicine And Pharmacology
NOT_YET_RECRUITINGBerlin, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.